EHA 2023 | Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier, MD, PhD, Lille Hospital University, Lille, France, gives an overview of the latest updates on CAR-T therapy for multiple myeloma. Dr Manier discusses clinical trials evaluating CAR-T therapy in earlier lines of therapy, including KarMMa-3 (NCT03651128) and CARTITUDE-4 (NCT04181827) in patients who have received 1-3 prior lines of therapy (LOT), and the CARTITUDE-5 (NCT04923893) and -6 (NCT05257083) studies evaluating CAR-T therapy in the frontline setting in transplant-ineligible and transplant-eligible patients respectively. Dr Manier also comments on strategies to improve the persistence and efficacy of CAR-T, including alternative antigens, dual-targeting, and shorter manufacturing time. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
